Amid converging pharma pricing trends, such as those triggered by the Inflation Reduction Act, companies must adopt novel operational practices and strategic approaches in line with new parameters for ...

Bob Mauch's leadership at Cencora focuses on digital transformation, talent development, and growth-oriented investments to ...

Kenvue opposes a Citizen Petition to change Tylenol's pregnancy warning, citing lack of scientific evidence for claims ...

In today’s Pharmaceutical Executive Daily, we cover Merck’s $70 billion expansion of U.S. operations, the FDA’s latest approvals for Novo Nordisk’s Rybelsus and Roche’s Gazyva, and a new digital ...

Novo Nordisk will hold an Extraordinary General Meeting to elect new board members due to a disagreement with the Foundation ...

The MFN pricing approach, while politically attractive, raises complex questions about how to fairly and sustainably price ...

In light of the recent Congressional Budget Office report highlighting the impact of lower National Institutes of Health ...

In today’s Pharmaceutical Executive Daily, we cover the FDA’s creation of a new National Priority Voucher Program, the market ...

Galapagos announced plans to scale back on its cell therapy business, while the company pursues new transformational business ...

Frontier Scientific Solutions, a contract service organization (CSO), and Air Transport Services Group, a provider of ...

The adoption of artificial intelligence (AI) has accelerated, yet its impact on R&D productivity remains underwhelming.

Pharmaceutical Executive: What impact will TrumpRx and other DTC programs have on drug availability? Jesse Mendelsohn: To be ...